Company Description
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial.
The company’s products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers.
Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG.
The company was founded in 2013 and is based in New Haven, Connecticut.
| Country | United States |
| Founded | 2015 |
| IPO Date | Sep 27, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 430 |
| CEO | John Houston |
Contact Details
Address: 5 Science Park, 395 Winchester Avenue New Haven, Connecticut 06511 United States | |
| Phone | 203 535 1456 |
| Website | arvinas.com |
Stock Details
| Ticker Symbol | ARVN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001655759 |
| CUSIP Number | 04335A105 |
| ISIN Number | US04335A1051 |
| Employer ID | 47-2566120 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John G. Houston Ph.D. | Chairperson, Chief Executive Officer and President |
| Andrew R. Saik | Chief Financial Officer and Treasurer |
| Angela M. Cacace Ph.D. | Chief Scientific Officer |
| Dr. Ian Taylor Ph.D. | President of Research and Development and Chairman of Scientific Advisory Board |
| Dr. Randy Teel Ph.D. | Chief Business Officer |
| Dr. Noah Berkowitz M.D., Ph.D. | Chief Medical Officer |
| David K. Loomis M.B.A. | Vice President and Chief Accounting Officer |
| Jared M. Freedberg J.D. | General Counsel and Corporate Secretary |
| Steve Weiss | Senior Vice President and Chief Human Resources Officer |
| Lisa Sinclair | Senior Vice President of Corporate Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 1, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 30, 2025 | SCHEDULE 13G/A | Filing |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Apr 4, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 144 | Filing |